Advertisement
Canada markets open in 1 hour 31 minutes
  • S&P/TSX

    21,639.10
    -59.00 (-0.27%)
     
  • S&P 500

    5,431.60
    -2.14 (-0.04%)
     
  • DOW

    38,589.16
    -57.94 (-0.15%)
     
  • CAD/USD

    0.7274
    -0.0010 (-0.13%)
     
  • CRUDE OIL

    78.75
    +0.30 (+0.38%)
     
  • Bitcoin CAD

    90,406.91
    -938.05 (-1.03%)
     
  • CMC Crypto 200

    1,370.34
    -17.82 (-1.28%)
     
  • GOLD FUTURES

    2,333.50
    -15.60 (-0.66%)
     
  • RUSSELL 2000

    2,006.16
    -32.75 (-1.61%)
     
  • 10-Yr Bond

    4.2130
    -0.0250 (-0.59%)
     
  • NASDAQ futures

    19,717.50
    +32.00 (+0.16%)
     
  • VOLATILITY

    13.07
    +0.41 (+3.24%)
     
  • FTSE

    8,148.44
    +1.58 (+0.02%)
     
  • NIKKEI 225

    38,102.44
    -712.12 (-1.83%)
     
  • CAD/EUR

    0.6789
    -0.0009 (-0.13%)
     

Stocks in play: Oncolytics Biotech® Inc.

Presented two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. One is a trial-in-progress abstract discussing cohort 5 of the GOBLET study, which will evaluate the combination of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with and without atezolizumab in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients. The second describes pelareorep's ability to induce the expansion of tumor-infiltrating lymphocytes (TILs) across multiple cancers and the correlation between TIL expansion and tumor response. Oncolytics Biotech® Inc. shares T.ONC are trading unchanged at $1.45.

Read: